Skip to main content


Fig. 2 | BMC Neurology

Fig. 2

From: Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

Fig. 2

Time to 3-month confirmed disability progressiona over 1 year. Assessed using Cox’s proportional hazards model adjusting for baseline EDSS score (≤3.5 vs. > 3.5) and age (< 40 vs. ≥40 years). aEDSS progression was defined as 1-point increase in EDSS score if the baseline EDSS score was < 6.0 or a 0.5-point increase if the baseline EDSS score was ≥6.0. (EDSS scores could be > 5 if scores increased between screening and baseline). CI: confidence interval; EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly

Back to article page